Redx Pharma plc Director/PDMR Shareholding (4613W)
November 14 2017 - 5:30AM
UK Regulatory
TIDMREDX
RNS Number : 4613W
Redx Pharma plc
14 November 2017
REDX PHARMA PLC
("Redx" or "the Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Alderley Park, November 14 2017- Redx Pharma (AIM:REDX), the
drug discovery and development company, announces that is has been
notified that Iain Ross, Executive Chairman, has today acquired
348,000 Redx ordinary shares at a price of 18.036 pence per share.
Following this, Mr Ross will hold 348,000 ordinary shares in the
Company, representing 0.28 per cent. of the issued share
capital.
Mr Ross purchased the shares through his self-invested personal
pension (SIPP) and the notification below, made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further details:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Iain Ross
--- ------------------------ -----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status Executive Chairman
--- ------------------------ -----------------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Redx Pharma plc
--- ------------------------ -----------------------------------------
b) LEI 213800HMS4EBXO589Y37
--- ------------------------ -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- -------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence
the financial ISIN: GB00BSNB6S51
instrument, type
of instrument
Identification
code
--- ------------------------ -----------------------------------------
b) Nature of the Purchase of shares through self-invested
transaction personal pension (SIPP)
--- ------------------------ -----------------------------------------
c) Price(s) and 348,000 ordinary shares at a price
volume(s) of 18.036 pence per share
--- ------------------------ -----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------------
e) Date of the transaction 14 November 2017
--- ------------------------ -----------------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ -----------------------------------------
For further information, please contact:
Redx Pharma Plc T: +44 1625
469 918
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated T: +44 20
Advisor & Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
FTI Consulting T: +44 20
3727 1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on
AIM (AIM:REDX). Redx is focused on creating and developing first,
or potentially best in class drugs, in specific areas of oncology
and fibrosis that address significant unmet medical need. Redx has
a significant in-house discovery team with proven world-class
chemistry capabilities.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUSUARBVAAAAA
(END) Dow Jones Newswires
November 14, 2017 06:30 ET (11:30 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024